proxyvotesnow.com

Home › Companies › BioCryst Pharmaceuticals, Inc. › 2025-2026

BioCryst Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings. Page generated 02 October 2026.

  • 10Reported items
  • 307Asset managers
  • 1,799Fund votes
  • 2026-06-11Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore BioCryst Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

How asset managers voted at the BioCryst Pharmaceuticals, Inc. 2025-2026 meeting

Each item below shows how the 307 asset managers that disclosed a BioCryst Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of BioCryst Pharmaceuticals, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To hold a non-binding, advisory vote regarding executive compensation.

SECTION 14A SAY-ON-PAY VOTES

Combines 5 wordings of this item as funds reported it.

68% fund support · no official result

FOR 67%AGAINST 32%

The 297 asset managers below cast 68% of the shares they voted on this item FOR (117,848,992 for, 55,425,729 against).

FOR: 117,848,992 (67.0%)AGAINST: 55,425,729 (31.5%)ABSTAIN: 28,219 (0.0%)SPLIT: 2,550,474 (1.5%)NOT VOTED: 1,317 (0.0%)
Largest asset managers voting on “To hold a non-binding, advisory vote regarding executive compensation.” at BioCryst Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard24,311,53010,122 20For
BlackRock2,743,33314,066,025 00Against
Janus Henderson15,186,7320 00For
State Street11,828,92398,759 00For
DEERFIELD MANAGEMENT COMPANY, L.P.10,862,6300 00For
RA CAPITAL MANAGEMENT, L.P.9,401,4070 00For
Aberdeen7,001,4020 00For
Fidelity1,359,7834,950,473 00Against
GEODE CAPITAL MANAGEMENT, LLC05,677,962 00Against
Charles Schwab4,705,8820 00For
Vestal Point Capital, LP04,158,394 00Against
Frazier Life Sciences Management, L.P.4,009,2400 00For
PERCEPTIVE ADVISORS LLC3,950,2680 00For
Nuveen3,693,6420 00For
TIAA3,595,5300 00For
GW&K Investment Management, LLC64,9800 00Split
Candriam S.C.A.02,286,841 00Against
Fisher Asset Management, LLC01,920,526 00Against
Invesco01,873,736 00Against
1919 Investment Counsel, LLC01,804,977 00Against
RICE HALL JAMES & ASSOCIATES, LLC1,784,7510 00For
Northern Trust01,684,027 00Against
Pacer Funds Trust1,568,4400 00For
JUPITER ASSET MANAGEMENT LTD01,464,307 00Against
ORBIMED ADVISORS LLC1,425,2000 00For

Showing the 25 largest of 297 asset managers. See all 297 in the interactive database.

2. TO APPROVE AN AMENDED AND RESTATED STOCK INCENTIVE PLAN, INCREASING THE NUMBER OF SHARES AVAILABLE FOR ISSUANCE UNDER THE STOCK INCENTIVE PLAN.

COMPENSATION

69% fund support · no official result

FOR 69%AGAINST 31%

The 76 asset managers below cast 69% of the shares they voted on this item FOR (43,014,933 for, 19,723,509 against).

FOR: 43,014,933 (68.5%)AGAINST: 19,723,509 (31.4%)ABSTAIN: 34,298 (0.1%)
Largest asset managers voting on “TO APPROVE AN AMENDED AND RESTATED STOCK INCENTIVE PLAN, INCREASING THE NUMBER OF SHARES AVAILABLE FOR ISSUANC” at BioCryst Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard22,273,71622,011 10For
BlackRock9,609,5200 00For
State Street5,3747,450,459 00Against
Fidelity5,144,361580,667 00For
TIAA03,595,530 00Against
Charles Schwab2,352,3900 00For
Aberdeen1,960,7320 00For
Pacer Funds Trust01,568,440 00Against
First Trust01,012,177 00Against
Invesco0750,281 00Against
AMG FUNDS0698,156 00Against
Equitable322,652183,774 2,3600For
Principal Exchange-Traded Funds0420,966 00Against
Dimensional0388,034 00Against
Goldman Sachs0333,308 00Against
Voya0322,895 00Against
Lincoln Financial29,488228,322 00Against
Virtus0256,833 00Against
JPMorgan215,9760 00For
Federated Hermes215,6100 00For
Northern Trust0202,239 00Against
ProShares0199,540 00Against
Putnam0181,722 00Against
Bridge Builder Trust143,06632,392 00For
ALGER FUNDS0155,560 00Against

Showing the 25 largest of 76 asset managers. See all 76 in the interactive database.

3. Election of Directors (each to serve until the 2029 Annual Meeting of Stockholders): Amy E. Mckee, M.D.

DIRECTOR ELECTIONS

Combines 7 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99.6%

The 75 asset managers below cast 100% of the shares they voted on this item FOR (62,607,167 for, 0 against).

FOR: 62,607,167 (99.6%)ABSTAIN: 230,314 (0.4%)
Largest asset managers voting on “Election of Directors (each to serve until the 2029 Annual Meeting of Stockholders): Amy E. Mckee, M.D.” at BioCryst Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard22,295,7160 140For
BlackRock9,609,5200 00For
State Street7,455,8330 00For
Fidelity5,725,0280 00For
TIAA3,595,5300 00For
Charles Schwab2,352,3900 00For
Aberdeen1,960,7320 00For
Pacer Funds Trust1,568,4400 00For
First Trust1,012,1770 00For
Invesco750,2810 00For
AMG FUNDS698,1560 00For
Equitable322,6520 183,7740For
Principal Exchange-Traded Funds420,9660 00For
Dimensional388,0340 00For
Goldman Sachs333,3080 00For
Voya322,8950 00For
Lincoln Financial257,8100 00For
Virtus256,8330 00For
CLEARWATER INVESTMENT TRUST234,4720 00For
JPMorgan215,9760 00For
Federated Hermes215,6100 00For
Northern Trust202,2390 00For
ProShares199,5400 00For
Putnam181,7220 00For
Bridge Builder Trust175,4580 00For

Showing the 25 largest of 75 asset managers. See all 75 in the interactive database.

4. Election of Directors (each to serve until the 2029 Annual Meeting of Stockholders): Jon P. Stonehouse

DIRECTOR ELECTIONS

Combines 6 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99.6%

The 75 asset managers below cast 100% of the shares they voted on this item FOR (62,593,598 for, 0 against).

FOR: 62,593,598 (99.6%)ABSTAIN: 243,882 (0.4%)
Largest asset managers voting on “Election of Directors (each to serve until the 2029 Annual Meeting of Stockholders): Jon P. Stonehouse” at BioCryst Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard22,273,8710 21,8580For
BlackRock9,609,5200 00For
State Street7,446,1150 9,7180For
Fidelity5,725,0280 00For
TIAA3,595,5300 00For
Charles Schwab2,352,3900 00For
Aberdeen1,960,7320 00For
Pacer Funds Trust1,568,4400 00For
First Trust1,012,1770 00For
Invesco750,2810 00For
AMG FUNDS698,1560 00For
Equitable322,6520 183,7740For
Principal Exchange-Traded Funds420,9660 00For
Dimensional388,0340 00For
Goldman Sachs333,3080 00For
Voya322,8950 00For
Lincoln Financial257,8100 00For
Virtus256,8330 00For
CLEARWATER INVESTMENT TRUST234,4720 00For
JPMorgan215,9760 00For
Federated Hermes215,6100 00For
Northern Trust202,2390 00For
ProShares199,5400 00For
Putnam181,7220 00For
Bridge Builder Trust175,4580 00For

Showing the 25 largest of 75 asset managers. See all 75 in the interactive database.

5. Election of Directors (each to serve until the 2029 Annual Meeting of Stockholders): Theresa M. Heggie

DIRECTOR ELECTIONS

Combines 6 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99.2%

The 75 asset managers below cast 100% of the shares they voted on this item FOR (62,361,697 for, 0 against).

FOR: 62,361,697 (99.2%)ABSTAIN: 475,784 (0.8%)
Largest asset managers voting on “Election of Directors (each to serve until the 2029 Annual Meeting of Stockholders): Theresa M. Heggie” at BioCryst Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard22,295,7100 200For
BlackRock9,609,5200 00For
State Street7,455,8330 00For
Fidelity5,725,0280 00For
TIAA3,595,5300 00For
Charles Schwab2,352,3900 00For
Aberdeen1,960,7320 00For
Pacer Funds Trust1,568,4400 00For
First Trust1,012,1770 00For
Invesco750,2810 00For
AMG FUNDS698,1560 00For
Equitable322,6520 183,7740For
Principal Exchange-Traded Funds420,9660 00For
Dimensional388,0340 00For
Goldman Sachs333,3080 00For
Voya322,8950 00For
Lincoln Financial228,3220 29,4880For
Virtus256,8330 00For
CLEARWATER INVESTMENT TRUST234,4720 00For
JPMorgan00 215,9760Abstain
Federated Hermes215,6100 00For
Northern Trust202,2390 00For
ProShares199,5400 00For
Putnam181,7220 00For
Bridge Builder Trust175,4580 00For

Showing the 25 largest of 75 asset managers. See all 75 in the interactive database.

6. TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS FOR 2026.

AUDIT-RELATED

99.7% fund support · no official result

FOR 99.6%

The 75 asset managers below cast 99.7% of the shares they voted on this item FOR (62,558,851 for, 173,381 against).

FOR: 62,558,851 (99.7%)AGAINST: 173,381 (0.3%)ABSTAIN: 27,217 (0.0%)
Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS FOR ” at BioCryst Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard22,283,01712,711 00For
BlackRock9,609,5200 00For
State Street7,452,8882,945 00For
Fidelity5,725,0280 00For
TIAA3,595,5300 00For
Charles Schwab2,352,3900 00For
Aberdeen1,960,7320 00For
Pacer Funds Trust1,568,4400 00For
First Trust1,012,1770 00For
Invesco750,2810 00For
AMG FUNDS698,1560 00For
Equitable508,7860 00For
Principal Exchange-Traded Funds420,9660 00For
Dimensional388,0340 00For
Goldman Sachs333,3080 00For
Voya322,8950 00For
Lincoln Financial257,8100 00For
Virtus256,8330 00For
JPMorgan215,9760 00For
Federated Hermes215,6100 00For
Northern Trust202,2390 00For
ProShares199,5400 00For
Putnam181,7220 00For
Bridge Builder Trust175,4580 00For
ALGER FUNDS0155,560 00Against

Showing the 25 largest of 75 asset managers. See all 75 in the interactive database.

7. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

97% fund support · no official result

FOR 97%

The 5 asset managers below cast 97% of the shares they voted on this item FOR (2,610,547 for, 93,310 against).

FOR: 2,610,547 (96.5%)AGAINST: 93,310 (3.5%)
Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at BioCryst Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Eversept Partners, LP2,566,1970 00For
CLEARWATER INVESTMENT TRUST080,390 00Against
Empirical Financial Services, LLC d.b.a. Empirical Wealth Ma41,4590 00For
Vinva Investment Management Ltd012,920 00Against
Convergence Investment Partners, LLC2,8910 00For

8. Amend Omnibus Stock Plan

COMPENSATION

97% fund support · no official result

FOR 97%

The 2 asset managers below cast 97% of the shares they voted on this item FOR (2,566,197 for, 80,390 against).

FOR: 2,566,197 (97.0%)AGAINST: 80,390 (3.0%)
Largest asset managers voting on “Amend Omnibus Stock Plan” at BioCryst Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Eversept Partners, LP2,566,1970 00For
CLEARWATER INVESTMENT TRUST080,390 00Against

9. COMPENSATION

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (320 for, 0 against).

FOR: 320 (100.0%)
Largest asset managers voting on “COMPENSATION” at BioCryst Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Members Trust Co2200 00For
Capital Group1000 00For

10. Say on Pay

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (1,237 for, 0 against).

FOR: 1,237 (100.0%)
Largest asset managers voting on “Say on Pay” at BioCryst Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
ArchPoint Investors7370 00For
Empower5000 00For

Largest BioCryst Pharmaceuticals, Inc. shareholders voting in 2025-2026

Ranked by the number of BioCryst Pharmaceuticals, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 254,162,660 shares outstanding at the time of that meeting.

Top BioCryst Pharmaceuticals, Inc. shareholders by shares voted, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 9.57%
2BlackRock 6.61%
3Janus Henderson 5.98%
4State Street 4.69%
5DEERFIELD MANAGEMENT COMPANY, L.P. 4.27%
6RA CAPITAL MANAGEMENT, L.P. 3.70%
7Aberdeen 2.75%
8Fidelity 2.48%
9GEODE CAPITAL MANAGEMENT, LLC 2.23%
10Charles Schwab 1.85%

Reported BioCryst Pharmaceuticals, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

BioCryst Pharmaceuticals, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder % outstanding Disclosure
The Vanguard Group 8.16% DEF14A
BlackRock, Inc. 6.88% DEF14A
RA Capital Management, L.P. 6.23% 13G
RA Capital Healthcare Fund, L.P. 6.02% DEF14A
STATE STREET CORPORATION 5.98% 13G
Deerfield Mgmt, L.P. 5.64% 13G
Deerfield Partners, L.P. 5.64% DEF14A
Vanguard Capital Management 5.10% 13G
Jon P. Stonehouse 2.17% DEF14A
Alane P. Barnes 0.51% DEF14A

Percentages above are of 254,162,660 shares outstanding, as reported by BioCryst Pharmaceuticals, Inc. on its Form 10-Q dated 2026-04-30 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from BioCryst Pharmaceuticals, Inc.’s 10-Q dated 2026-04-30. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At BioCryst Pharmaceuticals, Inc.'s shareholder meeting held 2026-06-11, in the 2025-2026 proxy season, 307 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,799 separate fund positions. Their filings are grouped here into 10 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. No official Form 8-K vote tally has been matched to this meeting, so this page states no certified outcome for its most widely held ballot item. On that item — To hold a non-binding, advisory vote regarding executive compensation. — the reporting funds cast 68% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

BioCryst Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).